ArticleThe Journal of urology2018
Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
Article in The Journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Association Between Biopsy PD-L1 Combined Positive Score and Pathological Upgrading at Radical Prostatectomy in Grade Group 1 Prostate Cancer: A Retrospective Study.International journal of molecular sciences · 2026Article
- Clinicopathologic profile of Filipino men with low-risk prostate cancer and predictors of unfavorable pathology at radical prostatectomy.Prostate international · 2026Article
- European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance.Insights into imaging · 2026Article
- Predictive models for biopsy upgrading in active surveillance for prostate cancer: a scoping review.World journal of urology · 2026Article
- The volume of Gleason grade group 1 prostate cancer at biopsy predicts unfavorable pathology but not upgrading after radical prostatectomy.International urology and nephrology · 2026Article
- Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance.The Prostate · 2025Article
- Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.World journal of urology · 2024Article
- Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts.The Journal of urology · 2024Article
- High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy.Radiation oncology (London, England) · 2024Article
- Adverse pathology after radical prostatectomy: the prognostic role of cumulative cancer length >6-mm threshold in prostate cancer-positive biopsies.Prostate international · 2019Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
purposeActive surveillance is often restricted to patients with low risk prostate cancer who have 3 or fewer positive cores. We aimed to identify predictors of adverse pathology results for low risk prostate cancer treated with radical prostatectomy and determine whether a threshold number of positive cores could help the decision process for active surveillance. MATERIALS AND
methodsA total of 3,359 men with low risk prostate cancer underwent radical prostatectomy between January 2000 and August 2016. We analyzed the relationship between biopsy core features and adverse pathology at radical prostatectomy, defined as Grade Group 3 or greater, seminal vesicle invasion or lymph node involvement.
resultsOf the 171 cases (5.1%) with adverse pathology findings at radical prostatectomy 144 (4.3%) were upgraded to Grade Group 3 or greater, 31 (0.9%) had seminal vesicle invasion and 15 (0.4%) had lymph node involvement. Prostate specific antigen and patient age were the only predictors of adverse pathology results. There was no significant association with the number of positive cores, the total mm of cancer or the maximum percent of cancer in any core. When we expanded the definition of adverse pathology to include Grade Group 2 and extraprostatic extension, the association between core features and outcome was statistically significant but clinically weak, and with no evidence of threshold effects.
conclusionsThere is little basis for excluding patients with otherwise low risk prostate cancer on biopsy from active surveillance based on criteria such as the number of positive cores or the maximum cancer involvement of biopsy cores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.